Associated with the conference there will be a half-day interactive workshop on Ocular Drug Delivery: Identifying Advances and Opportunities; taking place on Monday 28th of March. This workshop shall thoroughly investigate the current state of ocular drug delivery in pharmaceuticals and will provide invaluable advice on catering for unmet medical needs in the field, whilst identifying exiting new opportunities in the area.
Leading this workshop will be
Conference agenda
Overview of Ocular Pharmaceutical Products
Common dosage forms in Ophthalmology
Unmet medical needs
Challenges of Ocular Drug Delivery
The Ocular Drug Delivery Technologies
A fast growing industry
Success of a topic eye drop
Success of a intravitreal injection
Case study
Local Drug Delivery Approaches
Specific clinical diseases
Sustained local delivery
Implants
Biodegrable delivery systems
Chairman's opening remarks Howard Stevens, Professor, University Of Strathclyde Overcoming poor bioavailability through amorphous solid dispersions Filipe Gaspar, Particle Design Discipline Director, Hovione S A Increasing bioavailability – Strategies for overcoming biological barriers Andreas Schatzlein, Reader, School of Pharmacy, University of London Data-driven strategies in the development of controlled release formulations Alyson Connor, Senior Research Fellow, Quotient Clinical Nasal delivery of macromolecules – are we there yet? Lisbeth Illum, CEO , Critical Pharmaceuticals
Recent developments and success stories
Issues still to tackle
Novel applications
Parenteral biologics delivery: key challenges and perspectives Joel Richard, Senior Director, Head of Drug Product Development, IPSEN Injectable sustained release of proteins Andy Lewis, Director, Critical Pharmaceuticals Drug delivery to the eye: From ocular barriers to the approaches to enhance drug bioavailability Vitaliy Khutoryanskiy, Lecturer in Pharmaceutics, University of Reading Bioglass and bioceramics as delivery vehicles for controlled-release Xiang Zhang , Principal Consultant, Medical Materials, CERAM sd-rxRNA: The novel class of the RNAi compounds with potential therapeutic applications Dmitry Samarsky, Vice President of Technology Development, RXi Pharmaceuticals Time for a new look at drug delivery: the chronopharmaceutical opportunity Howard Stevens, Professor, University Of Strathclyde Chairman’s Closing Remarks and Close of Day One Howard Stevens, Professor, University Of Strathclyde Chairman's Opening Remarks Howard Stevens, Professor, University Of Strathclyde Nanotechnology: state-of-the-art in pharmaceutical applications Mario Maio, Director of Formulation & Process Development, Merck Serono Development and clinical production of microsphere formulations Gerben Moolhuizen, Chief Business Officer, Octo Plus Nanotechnologies tools in candidate selection for the intravenous route Didier Bazile, Global Head of Drug Delivery Technologies , Sanofi Aventis Hot melt extrusion concept and application Hassan Mohammad, Principal Scientist, Mundipharma International Intellectual Property issues in controlled release Gerry Kamstra, Partner, Bird & Bird Review of controlled release strategies for inhaled therapies Frank Thielmann, Senior Fellow, PDU Inhalation, Novartis Pharmaceuticals Gastroretention for oral controlled release of drugs Clive Wilson, Professor of Pharmaceutics, University of Strathclyde Approaches and gaps in establishing hypromellose matrix robustness Richard Elkes, Senior Research Scientist, Merck KGaA Topical delivery by multifunctional lipid liquid crystalline systems Fredrik Joabsson, Director, Drug Delivery Systems, Camurus A B Chairman’s Closing Remarks and Close of Day Two Howard Stevens, Professor, University Of Strathclyde
Workshops
Copthorne Tara Hotel 29 March 2011 London, United Kingdom
copyright ©
2024
SAE Media Group
|